laria, noting that it has assumed drug-distribution tasks that are beyond its capacities and that, as a result, hundreds of thousands of doses of combination therapy have gone undelivered in Angola, where more than 11,000 people died of malaria in 2005. At a time when more money than ever is pouring into global health, the WHO's perceived lack of leadership and the rivalries in which it and other organizations are engaged represent major problems; it would behoove Chan to tackle them.
Jha, for one, believes that Chan may be able to take a first step toward coordinating the efforts of all the rivals if she uses "the WHO bully pulpit," a unique asset. And indeed, Chan, who spent several weeks after her election meeting with Bill and Melinda Gates, Global Fund Executive Director Richard Feachem, and high-ranking officials at all the major international health agencies, said she had concluded that the WHO should hold a meeting of all the players "to identify priorities and decide who is doing what." In a January 22, 2007, address, she told the WHO executive board that the organization "has a great responsibility to channel [the] enthusiasm, activity, and money" of myriad global health players into a "cohesive and compelling" public health agenda that brings "clear and measurable benefits to countries and their populations."
As colleagues at the WHO will attest, if Chan is holding a meeting, the other players will come.
And that's when her leadership -and her independence -will truly be tested.
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Improving Global Health -Margaret Chan at the WHO I n early 2005, physicians at a rural hospital in KwaZulu-Natal, a province of South Africa, were concerned by a high rate of rapid death among patients infected with the human immunodeficiency virus (HIV) who also had tuberculosis. A study revealed the presence not only of multidrug-resistant (MDR) tuberculosis but also what came to be called extensively drug-resistant (XDR) tuberculosis. XDR tuberculosis is caused by a strain of Mycobacterium tuberculosis resistant to isoniazid and rifampin (which defines MDR tuberculosis) in addition to any fluoroquinolone and at least one of the three following injectable drugs: capreomycin, kanamycin, and amikacin. Of 53 patients with XDR tuberculosis, 55% claimed they had never been treated (implying that they had primary infection with an XDR strain of M. tuberculosis); two thirds had recently been hospitalized; and all 44 who underwent testing were HIV-positive. All but one of the patients died of tuberculosis, with a median survival period of only 16 days from the time the first sputum specimen was collected. Genotyping analysis revealed that 85% of the 46 isolates tested belonged to the KwaZulu-Natal (KZN) family of tuberculosis strains, which had been recognized in the province for a decade. In the fall of 2006, international experts agreed on the laboratory case definition of XDR tuberculosis; a framework for action on the clinical management of suspected XDR tuberculosis; implications for national tuberculosis-control programs; protection of health care workers; surveillance; and advocacy, communication, and social mobilization. 3 The global threat of XDR tuberculosis has great significance for the public health field. For one thing, its very existence is a reflection of weaknesses in tuberculosis management, which should minimize the emergence of drug resistance. Early, accurate diagnosis and immediate, proper curative treatment, supported and supervised so that drugs are taken for the appropriate duration, are key to tuberculosis control. Inadequate drug regimens select out drugresistant strains, which then proliferate. Further treatment errors repeat the cycle, leading to strains that are resistant to other drugs, until MDR tuberculosis is created.
XDR Tuberculosis -Implications for Global Public Health
The recipe for XDR tuberculosis is the same -the inappropriate use of second-line drugs in a patient for whom first-line drugs are failing. Patients then spread the infection to close contacts, who acquire primary XDR tuberculosis. Multiple errors have probably contributed to the development of XDR disease in South Africa.
Solutions that interrupt this cycle are urgently needed. The most basic requirement is an effective disease-control infrastructure, starting with muchstrengthened laboratory capacity. Diagnosis based on sputum-smear microscopy and rapid liquid-culture methods followed by the provision of appropriate support for patients and strict supervision of treatment until cure are the basis of tuberculosis control. Compliance must be maximized to prevent the emergence of drug resistance.
Prevention, however, is insufficient once drug-resistant tuberculosis has spread. Immediate detection through rapid drugsusceptibility testing is necessary to ensure that patients receive a quick diagnosis and adequate treatment and that transmission of the disease is thereby interrupted. Such treatment requires access to second-line drugs, which are more costly, more toxic, and weaker than first-line drugs. Second-line treatment must be given for at least 18 months under strict monitoring and supervision, and patients must receive counseling and support, since further development of drug resistance would render them virtually untreatable. 4 New classes of anti- Prevalence of MDR tuberculosis among new cases 1.0%-2.9% 3.0%-6.4% ≥ 6.5%
Reported cases of XDR tuberculosis
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Data are from the World Health Organization.
tuberculosis drugs are unlikely to become available for at least another few years. XDR tuberculosis also has major implications for the care of patients with HIV and for HIV control, because a high prevalence of HIV predicts extreme vulnerability to tuberculosis. All available public health measures must be implemented when these diseases converge, starting with DOTS, the essential package of tuberculosis-control intervention based on diagnosis and treatment of infectious cases, and HIV-AIDS prevention and treatment. Antiretroviral drugs protect against tuberculosis by restoring patients' immunocompetence. Tuberculosis screening and chemoprophylaxis are essential in patients who are HIV-positive, as are antiretroviral treatment and the use of trimethoprim-sulfamethoxazole for patients with tuberculosis. Furthermore, hospital infection-control measures must be strengthened to prevent transmission among hospitalized patients and health care workers.
The development of XDR tuberculosis reveals weaknesses in primary care diagnostic services. Patients with cough often present at the nearest clinic, and if they have tuberculosis that is not promptly diagnosed and treated, they will spread the disease. And if tuberculosis isolates are not tested for drug susceptibility from the outset, resistance may be detected too late to permit a cure. These interventions require substantial primary care capacity and training of health care workers in recognizing suspected cases of tuberculosis, making diagnoses, supervising treatment, and counseling patients. Well-trained laboratory technicians are also of paramount importance for ensuring proper diagnosis.
In addition, the need to contain XDR tuberculosis places major demands on surveillance systems. Most current information on drug resistance comes from surveys, since routine drug-susceptibility testing has been the privilege of rich countries. This situation must change rapidly in areas affected by XDR tuberculosis. Information is essential for building and monitoring a response, and only computerized information systems allow sufficiently rapid exchange of information within and between countries. The 2005 International Health Regulations, which take effect in June 2007, provide a framework that identifies the roles of the WHO and national governments in identifying and responding to public health emergencies and sharing relevant information. Effective implementation of these regulations requires much more effective national surveillance and response systems -and therefore the mobilization of resources.
XDR tuberculosis has exposed the dearth of new tools for tuberculosis control. Although the current diagnostic tests and drugs can control tuberculosis if rigorously applied, the lack of easyto-use tests that produce rapid results reflects a lack of awareness of the magnitude of the problem. Ideally, if tuberculosis is suspected, it should be diagnosed at the point of care, and information about drug susceptibility should be obtained rapidly to guide treatment decisions. In most countries, this ideal is not achieved because of insufficient primary care services and the lack of adequate laboratories and of tools permitting easy, prompt detection of drug resistance. To correct these deficiencies, governments and international aid partners must invest in building a proper care and laboratory infrastructure, and research on better diagnostics must be intensified without delay.
Similarly, the lack of new classes of antituberculosis drugs has made treatment of drugresistant tuberculosis challenging. New treatment regimens probably will not be available for several years -hence the imperative to preserve the effectiveness of current drugs by making sure that no second-line drugs are used without proper supervision. An effective vaccine would be the most powerful tool for preventing tuberculosis and drug resistance, but a vaccine is not anticipated anytime soon. We must invest in research and development for better tools while maintaining the efficacy of the tools we have available today.
All evidence suggests that XDR tuberculosis reflects a failure to implement the measures recommended in the WHO's Stop TB Strategy. 5 This strategy emphasizes expanding high-quality DOTS programs, addressing HIV-associated tuberculosis and drug resistance, strengthening health care systems and primary care services, encouraging all providers to follow good practices, empowering patients and communities to improve health, and enabling and promoting research. These measures ultimately require political commitment and will, and in many countries, health is still not a top priority. But we now have an opportunity to prioritize tuberculosis control and research efforts, energized by the appearance of highly resistant strains that may not be halted unless imme-
